Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Hope S. Rugo(University of California, San Francisco), Sara M. Tolaney(Dana-Farber Cancer Institute)
Cited by 81
Related Papers
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
|Clinical Cancer Research|2025|7